What is a stock summary page? Click here for an overview.
Business Description
Arcutis Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03969K1088
Share Class Description:
ARQT: Ordinary SharesDescription
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.06 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.7 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.73 | |||||
| Beneish M-Score | -0.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.9 | |||||
| 3-Year EPS without NRI Growth Rate | 34.8 | |||||
| 3-Year FCF Growth Rate | 35.1 | |||||
| 3-Year Book Growth Rate | -39.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 45.65 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.71 | |||||
| 9-Day RSI | 49.68 | |||||
| 14-Day RSI | 53.83 | |||||
| 3-1 Month Momentum % | -4.27 | |||||
| 6-1 Month Momentum % | 46.26 | |||||
| 12-1 Month Momentum % | 38.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.15 | |||||
| Quick Ratio | 3.97 | |||||
| Cash Ratio | 2.81 | |||||
| Days Inventory | 262.58 | |||||
| Days Sales Outstanding | 88.98 | |||||
| Days Payable | 253.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -32.9 | |||||
| Shareholder Yield % | -7.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.27 | |||||
| Operating Margin % | -65.33 | |||||
| Net Margin % | -71.25 | |||||
| FCF Margin % | -57.07 | |||||
| ROE % | -86 | |||||
| ROA % | -34.14 | |||||
| ROIC % | -210.18 | |||||
| 3-Year ROIIC % | 166.59 | |||||
| ROC (Joel Greenblatt) % | -476.1 | |||||
| ROCE % | -33.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.67 | |||||
| PB Ratio | 11.77 | |||||
| Price-to-Tangible-Book | 12.48 | |||||
| EV-to-EBIT | -15.58 | |||||
| EV-to-EBITDA | -15.95 | |||||
| EV-to-Revenue | 8.9 | |||||
| EV-to-Forward-Revenue | 6.15 | |||||
| EV-to-FCF | -15.59 | |||||
| Price-to-Net-Current-Asset-Value | 12.79 | |||||
| Price-to-Net-Cash | 50.74 | |||||
| Earnings Yield (Greenblatt) % | -6.42 | |||||
| FCF Yield % | -6.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARQT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arcutis Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 196.542 | ||
| EPS (TTM) ($) | -1.16 | ||
| Beta | 2.19 | ||
| 3-Year Sharpe Ratio | 0.37 | ||
| 3-Year Sortino Ratio | 0.67 | ||
| Volatility % | 66.1 | ||
| 14-Day RSI | 53.83 | ||
| 14-Day ATR ($) | 1.075061 | ||
| 20-Day SMA ($) | 15.5025 | ||
| 12-1 Month Momentum % | 38.14 | ||
| 52-Week Range ($) | 6.99 - 17.75 | ||
| Shares Outstanding (Mil) | 118.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcutis Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arcutis Biotherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arcutis Biotherapeutics Inc Frequently Asked Questions
What is Arcutis Biotherapeutics Inc(ARQT)'s stock price today?
The current price of ARQT is $15.73. The 52 week high of ARQT is $17.75 and 52 week low is $6.99.
When is next earnings date of Arcutis Biotherapeutics Inc(ARQT)?
The next earnings date of Arcutis Biotherapeutics Inc(ARQT) is 2025-05-14 Est..
Does Arcutis Biotherapeutics Inc(ARQT) pay dividends? If so, how much?
Arcutis Biotherapeutics Inc(ARQT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers